Filing Analysis
Park Dental Partners, Inc. reported the results of its 2026 Annual Meeting of Shareholders held on May 29, 2026. Shareholders elected Christopher C. Smith as a Class II director and ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting held on May 29, 2026.
- Christopher C. Smith was elected as a Class II director to serve until the 2029 annual meeting.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Quorum was established with 5,279,595 shares represented out of 6,608,919 shares entitled to vote.
Park Dental Partners, Inc. announced its financial results for the first quarter ended March 31, 2026. The company scheduled a public conference call for May 14, 2026, to discuss the performance.
📋 Key Facts
- Announced Q1 2026 financial results for the period ending March 31, 2026
- Earnings conference call scheduled for May 14, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Press release included as Exhibit 99.1
Park Dental Partners, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company scheduled a conference call for February 26, 2026, to discuss the performance.
📋 Key Facts
- Announced Q4 and full year 2025 results on February 25, 2026
- Reporting period ended December 31, 2025
- Conference call scheduled for February 26, 2026
- Press release furnished as Exhibit 99.1
Park Dental Partners amended its existing credit agreement with U.S. Bank National Association to extend its $15M revolving line of credit to March 2029 and align covenants with public-company requirements following its December 2025 IPO. The amendment also permits previously disclosed shareholder promissory notes for equity-vesting tax obligations.
🚩 Red Flags
- Maximum Total Cash Flow Leverage Ratio of 4.00x is moderately elevated, suggesting meaningful debt load relative to cash flow
- Related-party element: shareholder promissory notes to doctor shareholders for equity-vesting tax liquidity, though previously disclosed in S-1 and prospectus
- Multiple affiliated borrower entities increase structural complexity and cross-default risk
📋 Key Facts
- Amendment dated February 13, 2026 (effective January 1, 2026) to Amended and Restated Credit Agreement with U.S. Bank National Association
- Credit facility consists of a $15M revolving line of credit and a $13M term loan ($28M total)
- Revolving line maturity extended to March 27, 2029
- Financial covenants set at minimum Fixed Charge Coverage Ratio of 1.15:1.00 and maximum Total Cash Flow Leverage Ratio of 4.00:1.00
- Quarterly financial statements must be delivered within 45 days after each of Q1, Q2, and Q3
- Amendment permits shareholder promissory notes for tax obligations arising from equity vesting at IPO — previously disclosed in S-1 (Registration No. 333-290001) filed September 24, 2025 and final prospectus dated December 2, 2025
- Company IPO'd on Nasdaq Capital Market in December 2025; classified as emerging growth company
- Borrowers include the Company plus five affiliated entities: PDG P.A., Dental Specialists of Minnesota PLLC, Orthodontic Specialists of Minnesota PLLC, The Facial Pain Center PLLC, and PDP MN LLC